AlphaMaven

Company Logo'

Venture Capital

BioHealth Capital Fund

Healing the World One Investment at a Time
Back

Venture Capital

BioHealth Innovation Newsletter - March 9, 2021

posted by BioHealth Capital Fund
8mos ago 499

To view the newsletter click here.

  • Digital Health Forum Presented by EAGB and BioHealth Innovation Registration, Thu, Mar 25, 2021 at 1:00 PM | Eventbrite
  • VIRTUAL SBIR and OTHER NON-DILUTIVE FUNDING SOURCES WORKSHOP with 1:1 PARTNERING – March 17-19, 2021
  • Dr. Dipanjan Pan and Phil Robilotto of the University of Maryland, Baltimore, join Rich Bendis on BioTalk
  • EIR Feedback (BHI)
  • BioHealth Capital Fund - Video PitchBook
  • GMU, University of Maryland join Melinda Gates-backed effort to boost tech diversity - Washington Business Journal
  • Ceres Nanosciences adding manufacturing facility, 50 jobs to improve Covid-19 tests - Washington Business Journal
  • Montgomery County Updates: Inaugural ‘Bio Boot Camp’ Classes Graduate as Part of Innovative County Workforce Initiative That Will Help Fill Jobs in Life Sciences Sector
  • TEDCO’s Seed Fund Invests $400K in Maryland HR Technology Start-ups | TEDCO
  • FASTER (Federal Authority for Science, Technology, Engineering and Research) Federal Labs: Leveraging Place, Talent and Technology
  • This research executive has done a lot to bring small businesses into the fold | Federal News Network
  • Emergent Biosolutions Seeks New Talent to Support Global COVID-19 Vaccination Push, Expanding Project Portfolio · BioBuzz
  • GSK to receive CARB-X funding to develop superbug vaccines - EPM Magazine
  • Emergent BioSolutions can make 1 billion Covid vaccine doses annually

To view the newsletter click here.


ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.